Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State

Overview

Journal Cancer Res

Specialty Oncology

Date 2017 May 17

PMID 28507050

Citations 59

Authors

Masoud H Manjili

Affiliations

Soon will be listed here.

Abstract

Species evolve by mutations and epigenetic changes acting on individuals in a population; tumors evolve by similar mechanisms at a cellular level in a tissue. This article reviews growing evidence about tumor dormancy and suggests that (i) cellular malignancy is a natural byproduct of evolutionary mechanisms, such as gene mutations and epigenetic modifications, which is manifested in the form of tumor dormancy in healthy individuals as well as in cancer survivors; (ii) cancer metastasis could be an early dissemination event that could occur during malignant dormancy even before primary cancer is clinically detectable; and (iii) chronic inflammation is a key factor in awakening dormant malignant cells at the primary site, leading to primary cancer development, and at distant sites, leading to advanced stage diseases. On the basis of this evidence, it is reasonable to propose that we are all cancer survivors rather than cancer-free individuals because of harboring dormant malignant cells in our organs. A better understanding of local and metastatic tumor dormancy could lead to novel cancer therapeutics for the prevention of cancer. .

Citing Articles

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.

PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.

Sensitivity to Environmental Stress and Adversity and Lung Cancer.

Chen Y, Lan Q, Yu J, Godbole D, Byun J, Amos C JAMA Netw Open. 2025; 8(1):e2457079.

PMID: 39878978 PMC: 11780474. DOI: 10.1001/jamanetworkopen.2024.57079.

Modeling tumors as complex ecosystems.

Aguade-Gorgorio G, Anderson A, Sole R iScience. 2024; 27(9):110699.

PMID: 39280631 PMC: 11402243. DOI: 10.1016/j.isci.2024.110699.

Therapy-induced senescent tumor cells in cancer relapse.

Song K, Wang J, Huang D J Natl Cancer Cent. 2024; 3(4):273-278.

PMID: 39036667 PMC: 11256611. DOI: 10.1016/j.jncc.2023.09.001.

Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy.

Cao J, Zhang Z, Zhou L, Luo M, Li L, Li B MedComm (2020). 2023; 4(6):e427.

PMID: 38045829 PMC: 10693315. DOI: 10.1002/mco2.427.

References

Fracol M, Datta J, Lowenfeld L, Xu S, Zhang P, Fisher C . Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes. Ann Surg Oncol. 2016; 24(2):407-417. DOI: 10.1245/s10434-016-5584-6. View

Hughes R, Qian B, Rowan C, Muthana M, Keklikoglou I, Olson O . Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Res. 2015; 75(17):3479-91. PMC: 5024531. DOI: 10.1158/0008-5472.CAN-14-3587. View

Jinno-Oue A, Shimizu N, Hamada N, Wada S, Tanaka A, Shinagawa M . Irradiation with carbon ion beams induces apoptosis, autophagy, and cellular senescence in a human glioma-derived cell line. Int J Radiat Oncol Biol Phys. 2009; 76(1):229-41. DOI: 10.1016/j.ijrobp.2009.08.054. View

Dalai S, Khoruzhenko S, Drake C, Jie C, Sadegh-Nasseri S . Resolution of infection promotes a state of dormancy and long survival of CD4 memory T cells. Immunol Cell Biol. 2011; 89(8):870-81. PMC: 3131418. DOI: 10.1038/icb.2011.2. View

Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein T . From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A. 2003; 100(13):7737-42. PMC: 164657. DOI: 10.1073/pnas.1331931100. View

Lipworth S, Hammond R, Baron V, Hu Y, Coates A, Gillespie S . Defining dormancy in mycobacterial disease. Tuberculosis (Edinb). 2016; 99:131-142. DOI: 10.1016/j.tube.2016.05.006. View

Frank S . Evolution in health and medicine Sackler colloquium: Somatic evolutionary genomics: mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration. Proc Natl Acad Sci U S A. 2009; 107 Suppl 1:1725-30. PMC: 2868288. DOI: 10.1073/pnas.0909343106. View

Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View

Payne K, Keim R, Graham L, Idowu M, Wan W, Wang X . Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells. J Leukoc Biol. 2016; 100(3):625-35. PMC: 4982610. DOI: 10.1189/jlb.5A1215-580R. View

10.

Harach H, Franssila K, Wasenius V . Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer. 1985; 56(3):531-8. DOI: 10.1002/1097-0142(19850801)56:3<531::aid-cncr2820560321>3.0.co;2-3. View

11.

Sakr W, Haas G, Cassin B, Pontes J, Crissman J . The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993; 150(2 Pt 1):379-85. DOI: 10.1016/s0022-5347(17)35487-3. View

12.

Namjoshi P, Showalter L, Czerniecki B, Koski G . T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells. Oncotarget. 2019; 10(57):6006-6020. PMC: 6800266. DOI: 10.18632/oncotarget.10298. View

13.

Seraj M, Samant R, Verderame M, Welch D . Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 2000; 60(11):2764-9. View

14.

Stephens J, Reich D, Goldstein D, Shin H, Smith M, Carrington M . Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet. 1998; 62(6):1507-15. PMC: 1377146. DOI: 10.1086/301867. View

15.

Bowers L, Maximo I, Brenner A, Beeram M, Hursting S, Price R . NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions. Cancer Res. 2014; 74(16):4446-57. DOI: 10.1158/0008-5472.CAN-13-3603. View

16.

Mayordomo J, Guerra J, Guijarro C, Garcia-Prats M, Gomez A, Lopez-Brea M . Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori. 1993; 79(5):321-4. DOI: 10.1177/030089169307900507. View

17.

Hallermalm K, Seki K, De Geer A, Motyka B, Bleackley R, Jager M . Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol. 2008; 180(6):3766-74. DOI: 10.4049/jimmunol.180.6.3766. View

18.

Ghajar C . Metastasis prevention by targeting the dormant niche. Nat Rev Cancer. 2015; 15(4):238-47. PMC: 4842412. DOI: 10.1038/nrc3910. View

19.

Romero I, Garrido C, Algarra I, Collado A, Garrido F, Garcia-Lora A . T lymphocytes restrain spontaneous metastases in permanent dormancy. Cancer Res. 2014; 74(7):1958-68. DOI: 10.1158/0008-5472.CAN-13-2084. View

20.

Weckermann D, Muller P, Wawroschek F, Harzmann R, Riethmuller G, Schlimok G . Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol. 2001; 166(2):699-703. View